Evaluating immunotherapy for rare mutations in lung cancer
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
This study is testing if immunotherapy can help people with advanced lung cancer who have rare mutations like ALK or KRAS.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 186 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Changsha, Hunan and 1 other locations) |
| Trial ID | NCT04777175 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the efficacy of immunotherapy in patients with advanced non-small cell lung cancer who have rare mutations such as ALK, KRAS, ERBB2, MET, RET, and BRAF. By analyzing data retrospectively, the study seeks to fill the gap in knowledge regarding how these specific mutations respond to immunotherapy treatments. The findings could provide valuable insights into personalized treatment options for patients with these rare mutations.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with advanced non-small cell lung cancer who have confirmed rare mutations.
Not a fit: Patients diagnosed with small cell lung cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective immunotherapy options for patients with rare mutations in non-small cell lung cancer.
How similar studies have performed: While this approach is relatively novel, similar studies have shown promise in evaluating targeted therapies for specific mutations in cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1.Diagnosed as advanced non-small cell lung cancer * 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation Exclusion Criteria: * The patient is diagnosed with small cell lung cancer
Where this trial is running
Changsha, Hunan and 1 other locations
- Hunan Cancer Hospital — Changsha, Hunan, China (Recruiting)
- Hunan Cancer hospital — Changsha, Hunan, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.